Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor

Cancer Letters

Volumn 308, Issue 1, 2011, Pages 91-99

  Halpern, Jennifer L ^a   Kilbarger, Amy ^a   Lynch, Conor C ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Breast to bone metastasis; Chemokine; CXCL; CXCR; Mesenchymal stem cell; Migration

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; CYTOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BREAST CANCER; CARCINOGENESIS; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; IN VITRO STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL1; CHEMOKINE CXCL5; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MESENCHYMAL STEM CELLS; MICE; NEOPLASTIC STEM CELLS; RECEPTORS, INTERLEUKIN-8B;

MURINAE; MUS; POLYOMAVIRUS;

EID: 79958093966     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.04.018     Document Type: Article

References (28)

1. Lipton A. Bisphosphonates and metastatic breast carcinoma. Cancer 2003, 97:848-853.
2. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007, 256:137-165.
3. Rot A., Von Andrian U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 2004, 22:891-928.
4. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., Guise T.A., Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
5. Sun Y.X., Schneider A., Jung Y., Wang J., Dai J., Cook K., Osman N.I., Koh-Paige A.J., Shim H., Pienta K.J., Keller E.T., McCauley L.K., Taichman R.S. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J. Bone Miner. Res. 2005, 20:318-329.
6. Liu S., Ginestier C., Ou S.J., Clouthier S.G., Patel S.H., Monville F., Korkaya H., Heath A., Dutcher J., Kleer C.G., Jung Y., Dontu G., Taichman R., Wicha M.S. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011, 71:614-624.
7. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
8. Shiozawa Y., Havens A.M., Pienta K.J., Taichman R.S. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008, 22:941-950.
9. Charbord P. Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther 2010, 21:1045-1056.
10. Ratliff B.B., Singh N., Yasuda K., Park H.C., Addabbo F., Ghaly T., Rajdev M., Jasmin J.F., Plotkin M., Lisanti M.P., Goligorsky M.S. Mesenchymal stem cells, used as bait, disclose tissue binding sites: a tool in the search for the niche?. Am J Pathol 2010, 177:873-883.
11. Zhang M., Mal N., Kiedrowski M., Chacko M., Askari A.T., Popovic Z.B., Koc O.N., Penn M.S. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J. 2007, 21:3197-3207.
12. Spaeth E., Klopp A., Dembinski J., Andreeff M., Marini F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008, 15:730-738.
13. Alfaro M.P., Pagni M., Vincent A., Atkinson J., Hill M.F., Cates J., Davidson J.M., Rottman J., Lee E., Young P.P. The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc. Natl. Acad. Sci. USA 2008, 105:18366-18371.
14. Alfaro M.P., Vincent A., Saraswati S., Thorne C.A., Hong C.C., Lee E., Young P.P. SFRP2 suppression of bone morphogenic protein (BMP) and Wnt signaling mediates mesenchymal stem cell (MSC) self-renewal promoting engraftment and myocardial repair. J Biol Chem 2010, 285:35645-35653.
15. Tropel P., Noel D., Platet N., Legrand P., Benabid A.L., Berger F. Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow. Exp. Cell Res. 2004, 295:395-406.
16. Halpern J., Lynch C.C., Fleming J., Hamming D., Martin M.D., Schwartz H.S., Matrisian L.M., Holt G.E. The application of a murine bone bioreactor as a model of tumor: bone interaction. Clin. Exp. Metastasis 2006, 23:345-356.
17. Martin M., Carter K., Thiolloy S., Lynch C.C., Matrisian L., Fingleton B. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res. 2008, 68. E-Pub ahead of print.
18. Thiolloy S., Halpern J., Holt G.E., Schwartz H.S., Mundy G.R., Matrisian L.M., Lynch C.C. Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Res. 2009, 69:6747-6755.
19. Devalaraja R.M., Nanney L.B., Du J., Qian Q., Yu Y., Devalaraja M.N., Richmond A. Delayed wound healing in CXCR2 knockout mice. J. Invest. Dermatol. 2000, 115:234-244.
20. Zhao M., Wimmer A., Trieu K., Discipio R.G., Schraufstatter I.U. Arrestin regulates MAPK activation and prevents NADPH oxidase-dependent death of cells expressing CXCR2. J. Biol. Chem. 2004, 279:49259-49267.
21. Yang G., Rosen D.G., Liu G., Yang F., Guo X., Xiao X., Xue F., Mercado-Uribe I., Huang J., Lin S.H., Mills G.B., Liu J. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin. Cancer Res. 2010, 16:3875-3886.
22. Freund A., Chauveau C., Brouillet J.P., Lucas A., Lacroix M., Licznar A., Vignon F., Lazennec G. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 2003, 22:256-265.
23. Snoussi K., Mahfoudh W., Bouaouina N., Fekih M., Khairi H., Helal A.N., Chouchane L. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer 2010, 10:283.
24. Owen J.D., Strieter R., Burdick M., Haghnegahdar H., Nanney L., Shattuck-Brandt R., Richmond A. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins. Int. J. Cancer 1997, 73:94-103.
25. Shen H., Schuster R., Lu B., Waltz S.E., Lentsch A.B. Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate 2006, 66:1721-1728.
26. Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., Carbone D.P., Matrisian L.M., Richmond A., Lin P.C., Moses H.L. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35.
27. Wang J.M., Griffin J.D., Rambaldi A., Chen Z.G., Mantovani A. Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J. Immunol. 1988, 141:575-579.
28. Matzer S.P., Zombou J., Sarau H.M., Rollinghoff M., Beuscher H.U. A synthetic, non-peptide CXCR2 antagonist blocks MIP-2-induced neutrophil migration in mice. Immunobiology 2004, 209:225-233.